» Articles » PMID: 34091457

MLH1 Exon 12 Gene Deletion Leading to Lynch Syndrome: A Case Report

Overview
Journal Oncol Res Treat
Specialty Oncology
Date 2021 Jun 6
PMID 34091457
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Deleterious heterozygous mutation of the MLH1 gene is an important cause of Lynch syndrome (LS), an autosomal dominant cancer caused by functional defects in the DNA mismatch repair (MMR) complex.

Case Report: The proband was a 35-year-old patient with confirmed colorectal cancer (CRC). Immunohistochemical (IHC) staining revealed the absence of MLH1 and PMS2 expression in the colorectal tissue specimens of the patient. Genetic counselling and tumor gene testing were performed using next-generation sequencing technology. The genetic tumor verification report showed the deletion of 4 bases in exon 12 of the tested MLH1 gene and a transcoding mutation. To our knowledge, this germline splice site mutation of MLH1 has not been reported before. The proband accepted several therapeutic regimens including PD-1 inhibitor and ultimately died of multiple organ failure.

Conclusion: Nonsense mutations and frameshift mutations of MMR genes are the most common causes of LS. Common mutations include those in MSH2, MLH1, MSH6, and PMS2. We report a mutation of MLH1 that has never been reported before. We recommend that patients with a history of colon or rectal cancer receive universal MMR or MSI testing and checkpoint inhibitor therapy for the first-line treatment of deficient MMR CRC.

Citing Articles

PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report.

Zhang H, Huang C, Wu J, Wang Z, Shao Y, Fu Z World J Clin Cases. 2022; 10(14):4669-4675.

PMID: 35663084 PMC: 9125291. DOI: 10.12998/wjcc.v10.i14.4669.


Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.

Roudko V, Bozkus C, Greenbaum B, Lucas A, Samstein R, Bhardwaj N Front Immunol. 2021; 12:757804.

PMID: 34630437 PMC: 8498209. DOI: 10.3389/fimmu.2021.757804.

References
1.
Arnold S, Buchanan D, Barker M, Jaskowski L, Walsh M, Birney G . Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat. 2009; 30(5):757-70. PMC: 2707453. DOI: 10.1002/humu.20936. View

2.
Lawes D, Pearson T, Sengupta S, Boulos P . The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer. 2005; 93(4):472-7. PMC: 2361590. DOI: 10.1038/sj.bjc.6602708. View

3.
Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

4.
Riley D, Barber M, Kienle G, Aronson J, von Schoen-Angerer T, Tugwell P . CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017; 89:218-235. DOI: 10.1016/j.jclinepi.2017.04.026. View

5.
Burgess A, Chia K, Haupt S, Thomas D, Haupt Y, Lim E . Clinical Overview of MDM2/X-Targeted Therapies. Front Oncol. 2016; 6:7. PMC: 4728205. DOI: 10.3389/fonc.2016.00007. View